Jerusalem, 8 January, 2026 (TPS-IL) — Israeli computational chemistry company Evogene Ltd. has partnered with Boston-based Unravel Biosciences to develop a first-in-class therapy aimed at repairing neurological damage in demyelinating disorders such as multiple sclerosis.
The collaboration combines Evogene’s AI-driven ChemPass platform for generative small-molecule design with Unravel’s patient-derived BioNAV system and Living Molecular Twins. Together, they aim to identify and optimize brain-penetrant molecules capable of restoring myelin and reversing neurological degeneration—an unmet need in current treatments that focus only on slowing disease progression. Clinical applications could extend to other complex neurodegenerative conditions.